VACUUM WOUND THERAPY WOUND DRESSING WITH VARIABLE PERFORMANCE ZONES

Abstract

A dressing for an open wound includes a cover layer dimensioned for positioning relative to a wound bed. The cover layer permits an evacuation of the space around the wound bed such that a sub-atmospheric pressure may be established to stimulate healing and facilitate the removal of fluid from the wound. Multiple performance zones in the cover layer allow the wound dressing to remain in position through repeated cycles of evacuation without placing undue strain on the wound bed. An outer peripheral zone may include a high peal-strength adhesive while an intermediate zone may include a shear resistant adhesive. A central zone may be devoid of any coating to maximize moisture transmission through cover layer.

Claims

1.-14. (canceled)

15. A wound dressing for use with a negative pressure wound therapy apparatus, the wound dressing comprising: a first adhesive and a second adhesive configured to form a seal with skin surrounding a wound and stabilize the wound dressing over the wound; wherein the first adhesive is arranged in a plurality of spaced apart, non-overlapping circular regions and the second adhesive is provided on a surface that surrounds the first adhesive; wherein the first adhesive is different from the second adhesive.

16. The wound dressing of claim 15, wherein the plurality of spaced apart, non-overlapping circular regions are arranged as a pattern.

17. The wound dressing of claim 15, wherein one of the first adhesive or the second adhesive comprises a high peal-strength adhesive and the other of the first adhesive or the second adhesive comprises a shear-resistant adhesive.

18. The wound dressing of claim 15, further comprising a fluid flow passage configured to be in fluidic communication with the negative pressure wound therapy apparatus.

19. The wound dressing of claim 18, wherein the fluid flow passage is configured to permit a one way flow of fluid away from the wound dressing when negative pressure is applied to the wound dressing.

20. The wound dressing of claim 18, wherein the fluid flow passage comprises a one way valve.

21. The wound dressing of claim 18, further comprising a port configured to be in fluid communication with the negative pressure wound therapy apparatus, wherein the port is configured to permit attachment of the fluid flow passage.

22. The wound dressing of claim 21, wherein the port comprises a flange about its perimeter.

23. The wound dressing of claim 22, wherein the flange comprises an adhesive on an underside of the flange for securement to an outer surface of the wound dressing.

24. The wound dressing of claim 15, further comprising a filler configured to absorb wound exudate within the wound dressing.

25. The wound dressing of claim 24, wherein the filler comprises polyolefin filaments arranged in a multi-strand bundle.

26. The wound dressing of claim 24, wherein the filler comprises an absorbent material.

27. The wound dressing of claim 24, wherein the filler comprises a non-woven gauze or reticulated foam.

28. The wound dressing of claim 24, wherein the filler comprises an antimicrobial material.

29. The wound dressing of claim 15, further comprising a negative pressure source in fluid communication with the wound dressing, the negative pressure source is configured to apply negative pressure to the wound dressing.

30. The wound dressing of claim 15, wherein the wound dressing comprises a cover layer with a central zone comprising a moisture vapor permeable membrane.

31. The wound dressing of claim 15, wherein the second adhesive is configured to laterally stabilize the wound dressing when negative pressure is applied to the wound dressing.

32. A wound dressing for use with a negative pressure wound therapy apparatus, the wound dressing comprising: a first zone comprising an adhesive; and a second zone comprising a gel; wherein the adhesive is arranged in a plurality of spaced apart, non-overlapping circular regions and the gel is provided on a surface that surrounds the adhesive.

Description

BRIEF DESCRIPTION OF THE DRAWINGS

[0012] The accompanying drawings, which are incorporated in and constitute a part of this specification, illustrate embodiments of the present disclosure and, together with the detailed description of the embodiments given below, serve to explain the principles of the disclosure.

[0013] FIG. 1 is an exploded perspective view of a vacuum wound therapy system in accordance with the present disclosure;

[0014] FIG. 2A is a perspective view of the vacuum wound therapy system of FIG. 1 assembled for use on a patient;

[0015] FIGS. 2B and 2C depict alternate assemblies of the vacuum wound therapy system;

[0016] FIG. 3A is a reverse angle perspective view of the cover layer of FIG. 1;

[0017] FIG. 3B depicts an alternate embodiment of the cover layer;

[0018] FIG. 4A is a cross sectional view of the vacuum wound therapy system of FIG. 1 in a first condition exhibiting a vacuum reservoir; and

[0019] FIG. 4B depicts the vacuum wound therapy system in a second condition wherein the vacuum reservoir is evacuated.

DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS

[0020] The wound dressing of the present disclosure promotes healing of a wound by providing a reservoir over the wound where a reduced pressure may be maintained. The reservoir subjects the wound to a sub-atmospheric pressure to effectively draw wound fluid, including liquid exudates, from the wound without the continuous use of a vacuum pump. Hence, vacuum pressure may be applied once, or in varying intervals depending on the nature and severity of the wound. The use of a wound dressing in this manner has been found to promote healing by reducing the probability of infection, stimulating the deposition of granulation tissue and other beneficial processes. The wound dressing of the present disclosure includes a cover layer having multiple performance zones to enhance the effect of a vacuum wound therapy treatment.

[0021] The attached figures illustrate exemplary embodiments of the present disclosure and are referenced to describe the embodiments depicted therein. Hereinafter, the disclosure will be described in detail by explaining the figures wherein like reference numerals represent like parts throughout the several views.

[0022] Referring initially to FIG. 1, a vacuum wound therapy system according to the present disclosure is depicted generally as 10 for use on a wound w surrounded by healthy skin s. The vacuum wound therapy system 10 includes a vacuum system 12 in fluid communication with a vacuum reservoir 14 (FIG. 4A) defined by or within the wound dressing 16. The vacuum system 12 includes a vacuum source 18 coupled to the dressing 16 through a one-way valve 20 and a vacuum tube 24. A collection canister 28 is provided for wound drainage and debris. The vacuum system 12 is adapted to provide a reduced pressure to the vacuum reservoir 14 appropriate to stimulate healing of the wound. A more detailed description of an appropriate vacuum system 12 is found in commonly assigned U.S. Patent Application Publication 2007/0066946, the entire contents of which are incorporated herein by reference.

[0023] Wound dressing 16 generally includes a contact layer 34, filler 38 and a cover layer 40 defining a plurality of performance zones. A backing layer 44 may be coated with various materials in a juxtaposed relation to define a peripheral zone 48, a first intermediate zone 52, a second intermediate zone 56 and a central zone 58 (FIG. 3A). Alternatively, each zone may comprise an independent layer positioned adjacent the wound bed w. Each layer is described in greater detail below.

[0024] Contact layer 34 may be sufficiently conformable to be positioned in direct contact with an irregularly shaped surface of a wound bed w. A thin film of polyethylene or other suitable non-adherent material may form the contact layer 34 to limit the adherence of filler 38 and other substances to the wound w. Apertures or perforations in the film permit fluids to pass through the contact layer 34, allowing for the sub-atmospheric pressure to penetrate into the wound w and for exudates to flow freely out of the wound w. By selecting an appropriate film material, the passage of wound exudate through contact layer 34 may be controlled so as to be substantially unidirectional to prevent wound exudate from flowing back into the wound. To promote a unidirectional flow, a conical apertured film, such as those provided by Tredegar Film Products of Richmond, VA, may be selected for forming contact layer 20. This type of film is arranged with apertures positioned at the peaks of cone shaped formations in the film material such that exudate encounters the film as an array of micro-funnels in one direction and an array of collecting basins in the other. Unidirectional flow of exudates may also be promoted by the selection of other materials including a lamination of layers having varying absorptive characteristics. One exemplary material, which may be used as a contact layer is sold under the trademark XEROFLO by Kendall Corp., a division of Covidien.

[0025] Filler 38 may be arranged over contact layer 34 to fill wound W to the level of the surrounding healthy skin s, or alternatively the wound w may be overfilled with filler 38. An absorbent material such as non-woven gauze or reticulated foam may be used for filler 38 to trap any exudate that migrates through contact layer 34. An antimicrobial dressing sold under the trademark KERLIX AMD by Kendall Corp., a division of Covidien, may be suitable for use as filler 38. To prevent adhesion to the wound w, the filler 38 may also comprise a material configured such that its fibers do not tend to protrude through apertures of contact layer 34 where they may become engulfed by newly forming granulation tissue. One particular type of material exhibiting this characteristic is often referred to as tow. The manufacturing process for synthetic fibers often includes an extrusion of an indeterminate length of continuous filaments, which are spun together to form fibers. Continuous lengths of un-spun filaments may be arranged in multi-strand bundles which are referred to as tow. A single length of tow formed from a hydrophobic material such as polyolefin may be laid in the wound bed w to form filler 38. This arrangement allows for a complete removal of filler 50 when the dressing 16 is changed without re-injuring the wound w.

[0026] Cover layer 40 may be placed over the wound W enclosing the contact layer and filler therein. The periphery of cover layer 40 extends laterally beyond the perimeter of the wound bed w so as to contact the healthy skin s to form a seal over the wound w. As depicted in FIG. 2A, an opening 60 may be provided or formed through the cover layer 40 to provide access for the vacuum tube 44 to communicate with the vacuum reservoir 14, or the vacuum tube 44 may be sealed under the periphery of the cover layer 40 as depicted in FIG. 2B. Alternatively, a distinct portal member or port 62 may be provided to facilitate fluid communication between the vacuum system 12 and the vacuum reservoir 14 as depicted in FIG. 2C. Port 62 may be configured as a rigid or semi rigid, low-profile component adapted to receive the vacuum tube 24 in a releasable and fluid-tight manner. The vacuum port 62 may be configured to include a wide and flexible flange 64 about its perimeter. The flange 64 permits an adhesive to be attached to either an underside of flange 64 for securement to an outer surface of cover layer 40, or to a top side of flange 64 to provide for mounting to the underside of the cover layer 40.

[0027] Referring now to FIG. 3A, cover layer 40 includes multiple performance zones 48, 52, 56 and 58 comprising various materials. A backing layer 44 may extend to the periphery of the cover layer 40 to provide a substrate for various coatings or materials defining the various performance zones 48, 52, 56 and 58. As depicted, each of the performance zones 48, 52, 56 and 58 is a continuous band arranged concentrically with respect to the others. The size, shape and position of the zones, however, may be varied according to the needs of the particular wound or treatment. For example, a cover layer 40A as depicted in FIG. 3B may be provided comprising a first intermediate zone 52 formed from a pattern of distinct shapes surrounded by second intermediate zone 56A. The various coatings may be laminated to the backing layer 44 or affixed by other appropriate means. The various materials forming layer 40 are described in greater detail herein below.

[0028] Backing layer 44 may be formed from a flexible polymeric membrane to act as a fluid barrier to allow for a sub-atmospheric pressure to be established in vacuum reservoir 14. The material's flexibility accommodates the pressure changes associated with the evacuation cycles in a VWT procedure. Backing layer 44 also serves as a microbial barrier preventing contaminants from entering the wound area. Preferably, the backing layer 44 is formed from a moisture vapor permeable membrane to promote the exchange of oxygen and moisture between the wound site and the atmosphere. A membrane that provides a sufficient moisture vapor transmission rate (MVTR) and is simultaneously impervious to liquid may be selected for use as backing layer 44. Another preferred membrane characteristic is the ability to stretch and conform to the compressed wound filler or wound bed. A membrane's tendency for elongation when subjected to a vacuum reduces the shear forces transitioned to the peri-wound area. One exemplary material for use in backing layer 44 is a transparent membrane sold under the trade name DURAFLEX by Deerfield Urethan, a Bayer Material Science Company. Other materials which may be suitable for use in a backing layer include the thin films marketed under the names POLYSKINII by Kendall Corp., a division of Covidien, TEGADERM by 3M of St. Paul, Minn. and OPSITE by Smith and Nephew PLC of London, UK. A central zone 58 of the cover layer is defined by the area of the backing layer 44 not covered with any material which would tend to lessen the MVTR.

[0029] At the periphery of the cover layer 40 is a peripheral zone 48 defined by a continuous layer of high peal-strength, pressure sensitive adhesive. The adhesive forms a seal with the skin s around the perimeter of the cover layer to prevent the ingress of atmospheric fluids under the edges of the cover layer 40 when a reduced pressure is established in the reservoir 14. The adhesive defining the peripheral zone 48 is adapted to prevent the loss of adhesion to the skin even when exposed to environmental factors such as exudates from the wound w or body movements by the patient. In general, the high peal-strength adhesive is adapted to resist inadvertent lift-off, roll or flagging, i.e., a failure of the dressing to adhere to itself, at the edges of the cover layer. The adhesive defining the peripheral zone 48 may include, for example, those adhesives included with the dressing sold under the trademark GELVA Multipolymer Solutions by CYTEC Surface Specialties Inc.

[0030] The high peal-strength adhesive defining peripheral zone 48 may be bonded to backing layer 44, or applied directly to the skin s surrounding the wound bed w. The adhesive should preferably be non-irritating and non-sensitizing to the contacted skin, and may be vapor moisture permeable to permit the contacted skin to transmit moisture. Preferably, the peripheral zone 48 and first intermediate zone 52 are positioned so as not to overlap the contact layer 34 as seen in FIGS. 4A and 4B. This arrangement facilitates the changing of certain individual components of the dressing, such as filler 38 without removing the entire dressing 16.

[0031] Disposed between the peripheral zone 48 and central zone 58 are first and second intermediate zones 52 and 56 respectively. First and second intermediate zones 52, 56 are defined by a layer of a substance for imparting a therapeutic effect or benefit to the wound w. As indicated above, first and second intermediate zones 52, 56 may be arranged as continuous bands concentric with central zone 58 as seen in FIG. 3A, as a pattern of distinct shapes as seen in FIG. 3B, or any other convenient arrangement.

[0032] First intermediate zone 52 may, for example, be defined by a layer of an adhesive that laterally stabilizes the dressing when a reduced pressure is applied to evacuate the reservoir. As seen in FIG. 4B, when the reservoir is evacuated, the cover layer may tend to flatten against the wound w. This may result in an outwardly directed force in the dressing 16 which may tend to separate the cover layer 40 from the skin s. Also, the shear forces in the cover layer 40 may be transmitted to the skin s, pulling apart newly forming granulation tissue and re-injuring the wound w. To counteract these tendencies, a shear-resistant adhesive may be selected for use in first intermediate zone 52. Since many high peal-strength adhesives are adapted primarily to resist upwardly directed forces, i.e., those forces tending to lift the cover layer from the skin, a high peal-strength adhesive defining the peripheral zone 48 may be supplemented with an adhesive particularly adapted to resist lateral forces defining the first intermediate zone 52. A shear-resistant adhesive, such as GMS 1753 manufactured by CYTEC Surface Specialties Inc., that is moisture vapor permeable and suitable for use on the skin, may be used to define first intermediate zone 52.

[0033] Second intermediate zone 56 may be defined by a layer of a distinct material for providing a therapeutic effect or benefit to the wound. For example, second intermediate zone 56 may be adapted for transdermal medicament delivery. A substance such as an anti-infective agent, an antimicrobial, antibiotic, analgesic, healing factor, vitamins, growth factors, debridement agents or nutrients may be coated on portions of backing layer 108 to define second intermediate zone 56. Alternatively, a hydrogel may be selected for use in second intermediate zone 56 to maintain a moist wound environment. As seen in FIG. 4B, second intermediate zone 56 may be in contact with filler 38 when the reservoir 14 is evacuated to permit transfer beneficial agents thereto. Filler 38 and contact layer 34 may be eliminated if appropriate allowing for second intermediate zone 56 to contact the wound bed directly. It is also contemplated that an additional attachment adhesive may be beneficial for use in second intermediate zone 56.

[0034] Although the foregoing disclosure has been described in some detail by way of illustration and example, for purposes of clarity or understanding, it will be obvious that certain changes and modifications may be practiced within the scope of the appended claims.